Revolutionising Oncology Medicine: A Precision Approach that Cuts Costs and Boosts ROI

By Danélia Botes

July 11, 2023

In a groundbreaking study published in Journal of Pharmaceutical Policy and Practice volume, an analysis was conducted on the R&D costs of oncology medicines. The analysis, based on data from company filings from 1997 to 2020, indicates that a precision approach to oncology medicine development using Companion Diagnostic (CDx) could significantly reduce costs and increase ROI.

Despite some missing data, primarily from larger pharmaceutical companies that have acquired smaller firms, the study still provides a robust picture of the R&D landscape. They found that the total R&D spend to develop an oncology medicine (inconsistent use of CDx) is $4432.1 m, a figure that is significantly reduced when a CDx-guided precision oncology approach is adopted.

While the World Health Organization (WHO) has called for more transparency in R&D costs, this study highlights the need for standardisation in reporting R&D spend. This is crucial for health systems to make well-informed decisions on healthcare policy and for the pharmaceutical industry to recover R&D costs and continue innovating.

Findings suggest that precision oncology medicines guided by CDx are not only less expensive to develop but also offer better value to stakeholders, including patients, payers, and the pharmaceutical industry. This approach not only reduces R&D spend but also accelerates the reimbursement process and requires a rethinking of market access strategies.

The implications are far-reaching, impacting drug discovery, market access, health outcomes, and industry policy. As the pharmaceutical industry realises the cost-effectiveness of precision oncology medicines, it presents challenges to ensure equitable treatment provision for all patients.

This study emphasises the need for a flexible CDx development framework to truly benefit patients and ensure that R&D spend in oncology medicine development is affordable to health systems. The industry should revisit the commercial model for precision medicines and their associated diagnostic/prognostic tests to capitalise on the benefits of precision medicine.

Reference url

Recent Posts

South African National Health Insurance Bill
          

High Court on South African National Health Insurance Bill

📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill

Global Perspective on Orphan Medicines
                

A Global Perspective on Orphan Medicines and Rare Diseases

Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here

            

The Impact of Universal Health Coverage on Poverty Reduction in Low and Middle-Income Countries

📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.